homepage-banner.jpg
Mereo-Biopharma---logo.png

Unlocking healthcare potential for patients

Leveraging our expertise to address unmet medical needs

Our Strategy

Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas.

Mereo BioPharma plans to build a rare and orphan disease commercial business based on products acquired from major pharmaceutical companies.

Find out more about our strategy

our products

Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharma AG.

Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies.

Pre-Clinical
Phase 1
Phase 2
Phase 3

BPS-804

Osteogenesis Imperfecta (OI)
PHASE 2B (POTENTIALLY PIVOTAL)

BGS-649

Hypogonadotropic Hypogonadism (HH) in Obese Men
Phase 2B

ACUMAPIMOD

Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Phase 2

Investors

Share Price

View Share Price Chart

Events and conferences

  • 19 May 2017 Mereo BioPharma presented at at the American Thoracic Society meeting in Washington, 19-24 May 2017
  • 24 Jan 2017 Mereo BioPharma presented at at the Shares Spotlight Evening in London
  • 10 Jan 2017 Mereo BioPharma Group plc presented at the 9th Annual Biotech Showcase, 11:00am PST (San Francisco, USA)
View All Events